Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 8 (2011), Issue 4 (April)

  1. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
    Prostate, 71(8): 899-907. [Abstract] [Full-text]
  2. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.
    Prostate, 71(8): 892-8. [Abstract] [Full-text]
  3. GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP).
    Prostate, 71(8): 881-91. [Abstract] [Full-text]
  4. Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice.
    Prostate, 71(8): 872-80. [Abstract] [Full-text]
  5. Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3-1 gene.
    Prostate, 71(8): 857-71. [Abstract] [Full-text]
  6. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.
    Prostate, 71(8): 846-56. [Abstract] [Full-text]
  7. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo.
    Prostate, 71(8): 835-45. [Abstract] [Full-text]
  8. Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.
    Prostate, 71(8): 824-34. [Abstract] [Full-text]
  9. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.
    Prostate, 71(8): 813-23. [Abstract] [Full-text]
  10. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB.
    Prostate, 71(8): 801-12. [Abstract] [Full-text]
  11. Contemporary management of metastatic castration-resistant prostate cancer.
    Curr Opin Urol, 21(3): 241-7. [Abstract] [Full-text]
  12. The effect of different control point sampling sequences on convergence of VMAT inverse planning.
    Phys Med Biol, 56(8): 2569-83. [Abstract] [Full-text]
  13. Fixed number of segments in unidirectional decompositions of fluence matrices for step-and-shoot IMRT.
    Phys Med Biol, 56(8): 2601-15. [Abstract] [Full-text]
  14. Open versus robotic-assisted radical prostatectomy: which is better?
    Curr Opin Urol, 21(3): 200-5. [Abstract] [Full-text]
  15. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.
    Curr Opin Urol, 21(3): 237-40. [Abstract] [Full-text]
  16. Robotic radical prostatectomy: a critical analysis of the impact on cancer control.
    Curr Opin Urol, 21(3): 179-84. [Abstract] [Full-text]
  17. Intermittent hormonal therapy for prostate cancer.
    Curr Opin Urol, 21(3): 248-51. [Abstract] [Full-text]
  18. Robotic-assisted laparoscopic prostatectomy: a critical analysis of its impact on urinary continence.
    Curr Opin Urol, 21(3): 185-94. [Abstract] [Full-text]
  19. Temporal characterization and in vitro comparison of cell survival following the delivery of 3D-conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT).
    Phys Med Biol, 56(8): 2445-57. [Abstract] [Full-text]
  20. The role of PET/computed tomography scan in the management of prostate cancer.
    Curr Opin Urol, 21(3): 230-6. [Abstract] [Full-text]
  21. Robotic radical prostatectomy: a critical analysis of surgical quality.
    Curr Opin Urol, 21(3): 195-9. [Abstract] [Full-text]
  22. Contemporary management of patients with T1a and T1b prostate cancer.
    Curr Opin Urol, 21(3): 252-6. [Abstract] [Full-text]
  23. Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patient.
    Curr Opin Urol, 21(3): 211-8. [Abstract] [Full-text]
  24. A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature.
    Curr Opin Urol, 21(3): 219-24. [Abstract] [Full-text]
  25. Surgical anatomy of the prostate in the era of radical robotic prostatectomy.
    Curr Opin Urol, 21(3): 173-8. [Abstract] [Full-text]
  26. Contemporary role of radiation therapy in the adjuvant or salvage setting following radical prostatectomy.
    Curr Opin Urol, 21(3): 206-10. [Abstract] [Full-text]
  27. Contemporary role of prostate cancer gene 3 in the management of prostate cancer.
    Curr Opin Urol, 21(3): 225-9. [Abstract] [Full-text]
  28. Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).
    Contemp Clin Trials, 32(3): 453-60. [Abstract] [Full-text]
  29. Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling.
    Exp Cell Res, 317(8): 1214-25. [Abstract] [Full-text]
  30. A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species.
    Free Radic Biol Med, 50(9): 1151-62. [Abstract] [Full-text]
  31. Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina.
    Patient Educ Couns, 83(2): 256-60. [Abstract] [Full-text]
  32. Mediated decision support in prostate cancer screening: a randomized controlled trial of decision counseling.
    Patient Educ Couns, 83(2): 240-6. [Abstract] [Full-text]
  33. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
    Eur J Pharmacol, 658(2): 98-107. [Abstract] [Full-text]
  34. Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects.
    Eur J Cancer, 47(7): 1072-9. [Abstract] [Full-text]
  35. Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer.
    Mol Med Report, 4(3): 419-24. [Abstract] [Full-text]
  36. Patients' perspectives on fecal incontinence after brachytherapy for localized prostate cancer.
    Dis Colon Rectum, 54(5): 615-21. [Abstract] [Full-text]
  37. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling.
    Cancer Invest, 29(4): 318-24. [Abstract] [Full-text]
  38. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil?
    Invest Radiol, 46(5): 301-6. [Abstract] [Full-text]
  39. Relation between pain and skeletal metastasis in patients with prostate or breast cancer.
    Clin Physiol Funct Imaging, 31(3): 193-5. [Abstract] [Full-text]
  40. Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results.
    Eur Radiol, 21(5): 1111-8. [Abstract] [Full-text]
  41. Prostate cancer stem cells and their potential roles in metastasis.
    J Surg Oncol, 103(6): 558-62. [Abstract] [Full-text]
  42. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    J Pathol, 224(1): 90-100. [Abstract] [Full-text]
  43. Overexpression of vimentin in canine prostatic carcinoma.
    J Comp Pathol, 144(4): 308-11. [Abstract] [Full-text]
  44. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.
    Int J Radiat Oncol Biol Phys, 80(1): 6-16. [Abstract] [Full-text]
  45. Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade.
    Int J Mol Med, 27(6): 811-9. [Abstract] [Full-text]
  46. Costunolide induces apoptosis through nuclear calcium2+ overload and DNA damage response in human prostate cancer.
    J Urol, 185(5): 1967-74. [Abstract] [Full-text]
  47. Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy.
    J Urol, 185(5): 1686-90. [Abstract] [Full-text]
  48. A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy.
    J Urol, 185(5): 1681-5. [Abstract] [Full-text]
  49. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study.
    J Urol, 185(5): 1674-80. [Abstract] [Full-text]
  50. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy.
    J Urol, 185(5): 1691-7. [Abstract] [Full-text]
  51. Overuse of imaging for staging low risk prostate cancer.
    J Urol, 185(5): 1645-9. [Abstract] [Full-text]
  52. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
    J Urol, 185(5): 1650-5. [Abstract] [Full-text]
  53. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    J Urol, 185(5): 1656-60. [Abstract] [Full-text]
  54. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy.
    J Urol, 185(5): 1661-5. [Abstract] [Full-text]
  55. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT).
    Int J Radiat Oncol Biol Phys, 80(1): 301-5. [Abstract] [Full-text]
  56. Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.
    J Cancer Res Clin Oncol, 137(5): 811-9. [Abstract] [Full-text]
  57. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen.
    Int J Radiat Oncol Biol Phys, 80(1): 62-8. [Abstract] [Full-text]
  58. Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.
    Int J Radiat Oncol Biol Phys, 80(1): 76-84. [Abstract] [Full-text]
  59. Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 80(1): 85-90. [Abstract] [Full-text]
  60. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Int J Radiat Oncol Biol Phys, 80(1): 55-61. [Abstract] [Full-text]
  61. A new formula for prostate cancer lymph node risk.
    Int J Radiat Oncol Biol Phys, 80(1): 69-75. [Abstract] [Full-text]
  62. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery.
    Cochrane Database Syst Rev, 4: CD008306. [Abstract] [Full-text]
  63. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery.
    Cochrane Database Syst Rev, 4: CD008306. [Abstract] [Full-text]
  64. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    Int J Clin Pract, 65(5): 559-66. [Abstract] [Full-text]
  65. Novel agents and new therapeutics in castration-resistant prostate cancer.
    Curr Opin Oncol, 23(3): 290-6. [Abstract] [Full-text]
  66. Clinical importance of lymph node density in predicting outcome of prostate cancer patients.
    J Surg Res, 167(2): 267-72. [Abstract] [Full-text]
  67. Impact of annual surgical volume on length of stay in patients undergoing minimally invasive prostatectomy: a population-based study.
    Eur J Surg Oncol, 37(5): 429-34. [Abstract] [Full-text]
  68. Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?
    Hum Pathol, 42(5): 702-9. [Abstract] [Full-text]
  69. Positive visualization of implanted devices with susceptibility gradient mapping using the original resolution.
    Magn Reson Med, 65(5): 1483-90. [Abstract] [Full-text]
  70. Cellular and molecular effects of the liposomal mTHPC derivative Foslipos in prostate carcinoma cells in vitro.
    Photodiagnosis Photodyn Ther, 8(2): 86-96. [Abstract] [Full-text]
  71. Comparison of quantum-dots- and fluorescein-isothiocyanate-based technology for detecting prostate-specific antigen expression in human prostate cancer.
    IET Nanobiotechnol, 5(2): 47. [Abstract] [Full-text]
  72. Accelerated T2 mapping for characterization of prostate cancer.
    Magn Reson Med, 65(5): 1400-6. [Abstract] [Full-text]
  73. Frequency-domain analysis of photoacoustic imaging data from prostate adenocarcinoma tumors in a murine model.
    Ultrasound Med Biol, 37(5): 834-9. [Abstract] [Full-text]
  74. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells.
    Biochim Biophys Acta, 1813(5): 683-94. [Abstract] [Full-text]
  75. External validation of a model to predict the survival of patients presenting with a spinal epidural metastasis.
    Cancer Metastasis Rev, 30(2): 153-9. [Abstract] [Full-text]
  76. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat model.
    J Nutr Biochem, 22(5): 502-10. [Abstract] [Full-text]
  77. Loss of cell surface TFII-I promotes apoptosis in prostate cancer cells stimulated with activated α₂ -macroglobulin.
    J Cell Biochem, 112(6): 1685-95. [Abstract] [Full-text]
  78. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer.
    Radiology, 259(2): 453-61. [Abstract] [Full-text]
  79. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.
    Int J Oncol, 38(6): 1759-66. [Abstract] [Full-text]
  80. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid™: mechanism of activity.
    Int J Oncol, 38(6): 1675-82. [Abstract] [Full-text]
  81. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
    Oncol Rep, 25(6): 1511-6. [Abstract] [Full-text]
  82. Pancratistatin induces apoptosis and autophagy in metastatic prostate cancer cells.
    Int J Oncol, 38(6): 1549-56. [Abstract] [Full-text]
  83. Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US.
    Radiology, 259(2): 583-91. [Abstract] [Full-text]
  84. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates.
    J Cell Biochem, 112(6): 1593-600. [Abstract] [Full-text]
  85. A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance.
    J Clin Epidemiol, 64(6): 628-36. [Abstract] [Full-text]
  86. Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells.
    J Cell Physiol, 226(7): 1889-96. [Abstract] [Full-text]
  87. Differential transformation capacity of Src family kinases during the initiation of prostate cancer.
    Proc Natl Acad Sci U S A, 108(16): 6579-84. [Abstract] [Full-text]
  88. Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process.
    Proc Natl Acad Sci U S A, 108(16): 6591-6. [Abstract] [Full-text]
  89. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
    J Clin Oncol, 29(12): 1517-24. [Abstract] [Full-text]
  90. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
    Nucl Med Commun, 32(6): 475-8. [Abstract] [Full-text]
  91. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    Cancer Immunol Immunother, 60(5): 715-30. [Abstract] [Full-text]
  92. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
    J Magn Reson Imaging, 33(5): 1160-70. [Abstract] [Full-text]
  93. Endorectal MRI after radiation therapy: questioning the sextant analysis.
    J Magn Reson Imaging, 33(5): 1086-90. [Abstract] [Full-text]
  94. Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population?
    Biomarkers, 16(3): 236-42. [Abstract] [Full-text]
  95. Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis.
    Ir J Med Sci, 180(2): 497-503. [Abstract] [Full-text]
  96. A rapid access diagnostic clinic for prostate cancer: the experience after one year.
    Ir J Med Sci, 180(2): 505-8. [Abstract] [Full-text]
  97. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.
    Oncogene, 30(16): 1868-79. [Abstract] [Full-text]
  98. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
    Clin Exp Metastasis, 28(5): 479-91. [Abstract] [Full-text]
  99. Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
    Am J Pathol, 178(5): 2367-76. [Abstract] [Full-text]
  100. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis.
    Chem Biol, 18(4): 476-84. [Abstract] [Full-text]
  101. T1 hyperintensity of bladder urine at prostate MRI: frequency and comparison with urinalysis findings.
    Clin Imaging, 35(3): 203-7. [Abstract] [Full-text]
  102. Identification of an interaction between the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor with protein kinase C-related kinase (PRK) 1: implications for prostate cancer.
    J Biol Chem, 286(17): 15440-57. [Abstract] [Full-text]
  103. γ-Tocotrienol induces growth arrest through a novel pathway with TGFβ2 in prostate cancer.
    Free Radic Biol Med, 50(10): 1344-54. [Abstract] [Full-text]
  104. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Mutagenesis, 26(3): 371-83. [Abstract] [Full-text]
  105. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    BJU Int, 107(9): 1369-73. [Abstract] [Full-text]
  106. Prostate cancer and diet: food for thought?
    BJU Int, 107(9): 1348-59. [Abstract] [Full-text]
  107. Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.
    Int J Urol, 18(5): 358-62. [Abstract] [Full-text]
  108. Use of Chinese medicine among prostate cancer patients in Taiwan: a retrospective longitudinal cohort study.
    Int J Urol, 18(5): 383-6. [Abstract] [Full-text]
  109. Antibiotics and observation have a similar impact on asymptomatic patients with a raised PSA.
    BJU Int, 107(10): 1576-81. [Abstract] [Full-text]
  110. Focal therapy in the management of localized prostate cancer.
    BJU Int, 107(9): 1362-8. [Abstract] [Full-text]
  111. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.
    Int J Cancer, 128(12): 2843-52. [Abstract] [Full-text]
  112. Decision-making in localized prostate cancer: lessons learned from an online support group.
    BJU Int, 107(10): 1570-5. [Abstract] [Full-text]
  113. Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens.
    BJU Int, 107(10): 1587-91. [Abstract] [Full-text]
  114. Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer.
    BJU Int, 107(9): 1400-3. [Abstract] [Full-text]
  115. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging.
    BJU Int, 107(9): 1411-8. [Abstract] [Full-text]
  116. Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer.
    BJU Int, 107(9): 1404-10. [Abstract] [Full-text]
  117. Cumulative summation graphs are a useful tool for monitoring positive surgical margin rates in robot-assisted radical prostatectomy.
    BJU Int, 107(10): 1648-52. [Abstract] [Full-text]
  118. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
    BJU Int, 107(10): 1562-9. [Abstract] [Full-text]
  119. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
    BJU Int, 107(10): 1582-6. [Abstract] [Full-text]
  120. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.
    BJU Int, 107(9): 1488-99. [Abstract] [Full-text]
  121. Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer.
    BJU Int, 107(9): 1419-24. [Abstract] [Full-text]
  122. Role of p115RhoGEF in the regulation of extracellular Ca(2+)-induced choline kinase activation and prostate cancer cell proliferation.
    Int J Cancer, 128(12): 2833-42. [Abstract] [Full-text]
  123. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.
    Cancer, 117(10): 2086-95. [Abstract] [Full-text]
  124. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
    Cancer, 117(10): 2077-85. [Abstract] [Full-text]
  125. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Cancer, 117(10): 2058-66. [Abstract] [Full-text]
  126. Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape.
    Proc Natl Acad Sci U S A, 108(17): 6853-6. [Abstract] [Full-text]
  127. The vanilloid capsaicin induces IL-6 secretion in prostate PC-3 cancer cells.
    Cytokine, 54(3): 330-7. [Abstract] [Full-text]
  128. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.
    Am J Physiol Endocrinol Metab, 300(5): E902-8. [Abstract] [Full-text]
  129. Patients' desire to preserve sexual activity and final decision for a nerve-sparing approach: results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study.
    J Sex Med, 8(5): 1495-502. [Abstract] [Full-text]
  130. Cutaneous metastasis of prostatic adenocarcinoma: a cautionary tale.
    J Cutan Pathol, 38(6): 521-4. [Abstract] [Full-text]
  131. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
    Eur Urol, 59(5): 832-40. [Abstract] [Full-text]
  132. Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients.
    Eur Urol, 59(5): 684-98. [Abstract] [Full-text]
  133. MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
    Eur Urol, 59(5): 671-81. [Abstract] [Full-text]
  134. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy.
    Eur Urol, 59(5): 702-7. [Abstract] [Full-text]
  135. Exosomes as biomarker treasure chests for prostate cancer.
    Eur Urol, 59(5): 823-31. [Abstract] [Full-text]
  136. Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function.
    Brachytherapy, 10(3): 195-200. [Abstract] [Full-text]
  137. A simple method for dose fusion from multimodality treatment of prostate cancer: brachytherapy to external beam therapy.
    Brachytherapy, 10(3): 214-20. [Abstract] [Full-text]
  138. Precedence for prostate brachytherapy.
    Brachytherapy, 10(3): 201-7. [Abstract] [Full-text]
  139. Effects of ellipsoid prostate deformation on dose delivery during permanent interstitial brachytherapy.
    Brachytherapy, 10(3): 208-13. [Abstract] [Full-text]
  140. Purification and direct transformation of epithelial progenitor cells from primary human prostate.
    Nat Protoc, 6(5): 656-67. [Abstract] [Full-text]
  141. Molecular diagnostics in urologic malignancies: a work in progress.
    Arch Pathol Lab Med, 135(5): 610-21. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

American Cancer Society's Complete Guide to Prostate Cancer

American Cancer Society's Complete Guide to Prostate Cancer